Universitätsklinikum Münster

Hospital


Location: Münster, Germany (DE) DE

ISNI: 0000000405514246

ROR: https://ror.org/01856cw59

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Impact of Fc gamma R variants on the response to alemtuzumab in multiple sclerosis (2019) Keller CW, Ruck T, Mchugh D, Pfeuffer S, Gross CC, Korsukewitz C, Melzer N, et al. Journal article Fatigue and depression predict health-related quality of life in patients with pediatric-onset multiple sclerosis (2019) Gravesande KSV, Blaschek A, Calabrese P, Rostasy K, Huppke P, Kessler JJ, Kalbe E, et al. Journal article S2k Guideline: Diagnosis in case of suspected Betalactam Antibiotic Hypersensitivity (2019) Wurpts G, Aberer W, Dickel H, Brehler R, Jakob T, Kreft B, Mahler V, et al. Journal article ARIA guideline 2019: treatment of allergic rhinitis in the German health system (2019) Klimek L, Bachert C, Pfaar O, Becker S, Bieber T, Brehler R, Buhl R, et al. Journal article Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group (2019) Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, et al. Journal article Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) Reinhardt A, Stichel D, Schrimpf D, Koelsche C, Wefers AK, Ebrahimi A, Sievers P, et al. Journal article Individualized targeting and optimization of multi-channel transcranial direct current stimulation in drug-resistant epilepsy (2019) Antonakakis M, Rampp S, Kellinghaus C, Wolters CH, Moeddel G Conference contribution KCNQ1 an unexpected mediator of cold avoidance (2019) Kiper AK, Wegner S, Kadala A, Bertoune MAR, Touska F, Matschke V, Wrobel E, et al. Conference contribution A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019) Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany (2019) Goebell P, Mueller L, Gruellich C, Reichert D, Boegemann M, Doerfel S, Von Der Heyde E, et al. Conference contribution